Oneview Healthcare Valuation
Is ONE undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ONE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ONE (A$0.31) is trading below our estimate of fair value (A$1.12)
Significantly Below Fair Value: ONE is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ONE?
Key metric: As ONE is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is ONE's PS Ratio? | |
|---|---|
| PS Ratio | 13.2x |
| Sales | €9.71m |
| Market Cap | €128.17m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 12.7x |
| Enterprise Value/EBITDA | -12.6x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does ONE's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.3x | ||
CGS Cogstate | 2.6x | 10.9% | AU$171.8m |
MDR MedAdvisor | 1.3x | 13.4% | AU$162.6m |
M7T Mach7 Technologies | 3x | 18.1% | AU$88.1m |
ALC Alcidion Group | 2.1x | 8.2% | AU$77.9m |
ONE Oneview Healthcare | 13.2x | 25.9% | AU$209.0m |
Price-To-Sales vs Peers: ONE is expensive based on its Price-To-Sales Ratio (13.2x) compared to the peer average (2.3x).
Price to Sales Ratio vs Industry
How does ONE's PS Ratio compare vs other companies in the AU Healthcare Services Industry?
Price-To-Sales vs Industry: ONE is expensive based on its Price-To-Sales Ratio (13.2x) compared to the Global Healthcare Services industry average (3x).
Price to Sales Ratio vs Fair Ratio
What is ONE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 13.2x |
| Fair PS Ratio | 5.3x |
Price-To-Sales vs Fair Ratio: ONE is expensive based on its Price-To-Sales Ratio (13.2x) compared to the estimated Fair Price-To-Sales Ratio (5.7x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | AU$0.31 | AU$0.46 +47.5% | 21.2% | AU$0.55 | AU$0.36 | n/a | 2 |
| Oct ’25 | AU$0.33 | AU$0.42 +27.2% | 33.6% | AU$0.56 | AU$0.28 | n/a | 2 |
| Sep ’25 | AU$0.40 | AU$0.44 +11.0% | 36.9% | AU$0.61 | AU$0.28 | n/a | 2 |
| Aug ’25 | AU$0.36 | AU$0.46 +26.8% | 40.4% | AU$0.65 | AU$0.28 | n/a | 2 |
| Jul ’25 | AU$0.39 | AU$0.46 +20.2% | 40.4% | AU$0.65 | AU$0.28 | n/a | 2 |
| Jun ’25 | AU$0.32 | AU$0.46 +44.6% | 40.4% | AU$0.65 | AU$0.28 | n/a | 2 |
| May ’25 | AU$0.28 | AU$0.46 +68.3% | 40.4% | AU$0.65 | AU$0.28 | n/a | 2 |
| Apr ’25 | AU$0.33 | AU$0.46 +42.8% | 39.6% | AU$0.65 | AU$0.28 | n/a | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
Cogstate
AU$171.8m
A neuroscience technology company, engages in the creation, validation, and commercialization of digital brain health assessments used in both academic and industry sponsored research.
CGS
AU$0.99
7D
4.7%
1Y
-31.4%
SDI
AU$127.8m
Engages in the research and development, manufacture, and marketing of dental restorative materials, whitening systems, and other dental materials in Australia, Europe, the United States, and Brazil.
SDI
AU$1.08
7D
5.4%
1Y
29.5%
Doctor Care Anywhere Group
AU$23.1m
Provides digital healthcare and development services in the United Kingdom, Australia, and the Republic of Ireland.
DOC
AU$0.063
7D
-10.0%
1Y
26.0%